AstraZeneca and CSPC Pharmaceutical Group announced a collaboration on experimental kidney disease drugs.
7 reports, 3 independent
Updated Sep 1
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 7
- Developments
- 2
- Repetition
- 71%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AstraZeneca and CSPC Pharmaceutical Group announced a collaboration on experimental kidney disease drugs.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.CSPC Pharmaceutical Group is headquartered in Shijiazhuang.1 source
Announced collaboration between AstraZeneca and CSPC on experimental kidney disease drugs.1 source
Keep exploring
The entities involved
-
AstraZeneca
British-Swedish pharmaceutical company
-
CSPC Pharmaceutical Group
pharmaceutical company based in Shijiazhuang, Hebei, China
Nothing else this week.
Related events
- Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.
- AstraZeneca's drug was tested in collaboration with Pfizer's drug.
- Amgen and AstraZeneca announced a collaborative development of a combination therapy.
- AstraZeneca and Innate Pharma S.A. are collaborating on developing a lead pharmaceutical program.